Vanguard Group Inc. Has $8.84 Billion Stock Holdings in Bristol Myers Squibb Company $BMY

Vanguard Group Inc. grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 0.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 195,984,009 shares of the biopharmaceutical company’s stock after buying an additional 1,058,803 shares during the quarter. Vanguard Group Inc. owned 9.63% of Bristol Myers Squibb worth $8,838,879,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BMY. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. boosted its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the last quarter. Total Investment Management Inc. bought a new stake in Bristol Myers Squibb during the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb in the 2nd quarter valued at $40,000. Finally, Mark Sheptoff Financial Planning LLC raised its position in Bristol Myers Squibb by 233.3% in the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 700 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

BMY has been the subject of several recent analyst reports. Piper Sandler reiterated an “overweight” rating and issued a $66.00 target price (up previously from $62.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 28th. HSBC reiterated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Morgan Stanley reaffirmed an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $59.20.

Bristol Myers Squibb Trading Up 1.3%

Shares of BMY stock opened at $60.64 on Tuesday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The firm has a market cap of $123.49 billion, a P/E ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29. The company has a 50 day moving average of $55.50 and a 200-day moving average of $49.61. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s revenue for the quarter was up 1.3% on a year-over-year basis. During the same period last year, the company posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.2%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend was Friday, January 2nd. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.